UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2023 P 1209-8
Program Prior Authorization/Notification – Lidocaine Patch
Medication Lidocaine Patch (Lidoderm®*), ZTLido™
P&T Approval Date 2/2017, 3/2018, 3/2019, 4/2020, 6/2021, 8/2021, 9/2022, 11/2023
Effective Date 2/1/2024
1. Background:
Lidocaine patch (Lidoderm) and ZTLido are indicated for the relief of pain associated with post-
herpetic neuralgia (PHN). The American Academy of Neurology recommends the use of lidocaine
patch as an option for the management of PHN. Evidence also exists in support of using lidocaine
patch for non-PHN neuropathies.
2. Coverage Criteriaa:
A. Initial Authorization
1. Lidocaine patch or ZTLido will be approved based on both of the following criteria:
a. One of the following:
(1) Diagnosis of post-herpetic neuralgia
(2) Diagnosis of neuropathic pain
-AND-
b. Patch will be applied only to intact skin
Initial authorization will be issued for 6 months.
B. Reauthorization
1. Lidocaine patch or ZTLido will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Reauthorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Applies to brand and generic lidocaine patches. Brand Lidoderm is typically excluded from coverage.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place
© 2023 UnitedHealthcare Services Inc.
1
4. References:
1. Baron, R., Allegri, M., Correa-Illanes, G., et al. The 5% Lidocaine-Medicated Plaster: Its
Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and
Clinical Evidence Supporting its Use. Pain Ther. 2016; 5: 149.
2. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of Painful Diabetic
Neuropathy. Report of the American Academy of Neurology, the American Association of
Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical
Medicine and Rehabilitation. Neurology. 2011 May 17; 76(20):1758-65.
3. Derry S, Wiffen PJ, Moore RA, et al. Topical Lidocaine for Neuropathic Pain in Adults (Review).
Cochrane Database of Systemic Reviews 2014; 7: 1-41.
4. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for Neuropathic Pain in Adults:
Systematic Review, Meta-analysis and Updated NeuPSIG Recommendations. The Lancet
Neurology. 2015; 14(2):162-173.
5. Gilron, Ian et al. Neuropathic Pain: Principles of Diagnosis and Treatment. Mayo Clinic
Proceedings, Volume 90, Issue 4, 532 – 545.
6. Hooten M, Thorson D, Bianco J, et al. Institute for Clinical Systems Improvement. Pain:
Assessment, Non-Opioid Treatment Approaches and Opioid Management. Updated August 2017.
https://www.icsi.org/_asset/f8rj09/Pain.pdf. Accessed September 13, 2023.
7. Lidoderm [package insert]. San Jose, CA: TPU Pharma; December 2022.
8. ZTLido [package insert]. San Diego, CA: Scilex Pharmaceuticals Inc; April 2021.
Program Prior Authorization/Notification – Lidoderm
Change Control
Date Change
2/2017 New program.
3/2018 Annual review with no change.
3/2019 Updated references. No changes to coverage criteria.
4/2020 Added ZTLido to program.
6/2021 Annual review. Updated references.
8/2021 Removed footnote on ZTLido, it is no longer excluded.
9/2022 Annual review. Added state mandate footnote.
11/2023 Annual review. Updated references.
© 2023 UnitedHealthcare Services Inc.
2